( July 28, 2025, 1:20 PM EDT) -- WASHINGTON, D.C. — A Federal Circuit U.S. Court of Appeals panel held July 25 that it lacks jurisdiction to consider a medicine maker’s request for changes to an arbitration award requiring royalty payments to another company for a patented active ingredient because the issues on appeal do not sound in patent law, transferring the case to the Second Circuit U.S. Court of Appeals....